Sugi Predict

Sugi Predict / Compounds / SCHEMBL3244565

SCHEMBL3244565

SCHEMBL3244565

CC(=O)Nc1ccnc(Br)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 5/20 0.56
▸ KDM4E B2RXH2 4/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ RAB9A P51151 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ MAPT P10636 3/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ GLA P06280 1/20 0.47
▸ TNNI3 P19429 1/20 0.47
▸ TNNT2 P45379 1/20 0.47
▸ TNNC1 P63316 1/20 0.47
▸ RUNX1 Q01196 1/20 0.47
▸ CBFB Q13951 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ CYP1A2 P05177 2/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ GRIN2D O15399 1/20 0.46
▸ GRIN3B O60391 1/20 0.46
▸ GRIN1 Q05586 1/20 0.46
▸ GRIN2A Q12879 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30566452 1.00 AR (0.56) ARKDM4EMEN1RAB9AKMT2A
SCHEMBL14920023 0.87 AR (0.55) ARMEN1RAB9AKMT2ANPC1
SCHEMBL2596857 0.83 AR (0.57) ARKDM4EKMT2AMAPTALDH1A1
SCHEMBL24150865 0.83 TDP1 (0.51) ARMAPTPOLB
SCHEMBL31078765 0.81 AR (0.52) ARMAPTNPC1ALDH1A1HSD17B10
SCHEMBL197857 0.81 KDM5A (0.54) KDM4EMEN1RAB9AKMT2AMAPT
SCHEMBL16303150 0.81 AR (0.52) ARKDM4EMEN1RAB9AKMT2A
SCHEMBL16013758 0.81 AR (0.59) ARMEN1RAB9AKMT2AJAK2
SCHEMBL14921017 0.80 AR (0.70) ARNPSR1
SCHEMBL5520229 0.79 KDM4E (0.49) KDM4EMEN1RAB9AKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2024-04-04 — — US disclosed
US-11926632-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2024-03-12 — — US disclosed
EP-4267585-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS Actelion Pharmaceuticals Ltd (CH) 2023-11-01 — — EP disclosed
CN-116802184-A Pyrazolothiazole carboxamides and their use as PDGFR inhibitors 埃科特莱茵药品有限公司 2023-09-22 — — CN disclosed
EP-4167982-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV Pharmaceuticals, Inc. (US) 2023-04-26 — — EP disclosed
US-20230046427-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-02-16 — — US disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 — — WO disclosed
WO-2021262596-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-12-30 — — WO disclosed
CN-107074812-B Substituted pyrimidine compounds 格吕伦塔尔有限公司 2020-08-21 — — CN disclosed
EP-3527561-A1 NOVEL SUBSTITUTED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2019-08-21 — — EP disclosed
EP-3169681-A1 NOVEL SUBSTITUTED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2017-05-24 — — EP disclosed
US-9593095-B2 Methods for the treatment of bacterial infections DUKE UNIVERSITY (US) 2017-03-14 — — US disclosed
US-20170066776-A1 Novel substituted pyrimidine compounds GRUENENTHAL GMBH (DE) 2017-03-09 — — US disclosed
US-9540349-B2 Substituted pyrimidine compounds GRUENENTHAL GMBH (DE) 2017-01-10 — — US disclosed
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 — — US disclosed
EP-3029031-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-06-08 — — EP disclosed
US-20160016937-A1 Novel substituted pyrimidine compounds GRUENENTHAL GMBH (DE) 2016-01-21 — — US disclosed
WO-2016008593-A1 NOVEL SUBSTITUTED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-01-21 — — WO disclosed
US-20140371194-A1 METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS THE UNIVERSITY OF KANSAS 2014-12-18 — — US disclosed
WO-2010057833-A1 COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY BIOMARIN IGA, LTD. (BS) 2010-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230046427-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, HRAS AR 2211/4885KDM4E 3236/4885MEN1 3606/4885
US-20160016937-A1 Novel substituted pyrimidine compounds PDE4A, PDE4B, TYMP AR 3601/4885KDM4E 1354/4885MEN1 3807/4885
US-11926632-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS AR 2211/4885KDM4E 3236/4885MEN1 3606/4885
US-20140371194-A1 METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS CRYAB, HSP90B1, SERPINB1 AR 4792/4885KDM4E 4127/4885MEN1 3527/4885
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS PDGFRA, PDGFRB, ABL1 AR 824/4885KDM4E 2700/4885MEN1 3001/4885
US-20160159773-A1 HETEROCYCLIC COMPOUND TYK2, SSB, UACA AR 4051/4885KDM4E 1049/4885MEN1 1167/4885
US-20170066776-A1 Novel substituted pyrimidine compounds PDE4A, PDE4B, TYMP AR 3601/4885KDM4E 1354/4885MEN1 3807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.